MPA Makes PBAC Submission

An eraser is used to erase a depiction of cancerous cells

MPA made a submission to the PBAC for the consideration of the reimbursement of Nivolumab (Opdivo) and ipilumimab (Yervoy) and we thank all those that contributed their stories. Real stories provide real insights and these are invaluable! The PBAC will meet in March to consider this treatment option for reimbursement and we will advise you of the outcomes once we have any news. MPA maintains that all patients deserve access to the best evidence based treatments available.

No One Needs to Face Melanoma Alone

If you or a loved one is affected by Melanoma and needs support, we’re here for you, because no one affected by melanoma walks alone. Contact us here.
Call the National Melanoma Support Line 1300 884 450 Call 1300 884 450
Book a referral for a Melanoma Nurse Telehealth appointment Find out more
Speak with our Melanoma Nurse Counsellor Find out more
Join a Melanoma Patients Australia Support Group Find out more

Search